Isoma, which launched last year, will use the funds to develop and clinically validate a molecular test for stratifying glioblastoma patients.
Investigators have established hundreds of patient-derived xenografts, cell lines, and tumor samples, which appear to represent a wide range of melanoma molecular subtypes.
The company has achieved even higher specificity than earlier data demonstrated, and is now building up its sales and marketing infrastructure for the planned launch of its lung cancer test.
OncoCyte is proceeding full-steam ahead on commercializing the gene expression-based test, pursuing CLIA certification and a Q2 2017 launch.
The partnership will place the Graham Cancer Center's Gene Editing Institute under the purview of the Wistar Institute's Molecular Screening Facility.
The partners will identify novel drug targets in cancer, aging, and immune disorders, for which PhoreMost will develop small-molecule therapeutics.
Researchers believe the expression of Gabra3 promotes breast cancer metastasis, but that an RNA-edited form of Gabra3 suppresses it.
Last year, Wistar researchers presented data showing that the test could distinguish patients with malignant lung nodules from those with benign or no nodules.
The partners will further develop a non-invasive, blood-based test for the early detection of lung cancer.
The consortium will conduct research into how metastatic breast cancer cells break away and spread to other organs.
Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.
Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.
In Science this week: research regulation and reporting requirement reform, and more.
With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.